Journal article
Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile
Leukemia & Lymphoma, Vol.56(1), pp.65-71
01/02/2015
DOI: 10.3109/10428194.2014.903589
PMCID: PMC4383134
PMID: 24625326
Abstract
Anthracycline-containing regimens (ACRs) are recommended for patients with diffuse large B-cell lymphoma (DLBCL). However, over 40% of elderly patients do not receive ACRs, possibly due to expected toxicities. We characterized treatment choices and compared the 3-year overall survival (OS) rates of 8262 Medicare beneficiaries diagnosed with DLBCL in 2000-2006 identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Of the cohort, 45% had ACR with rituximab (ACR-R), 13% had ACR without R, 6% had non-ACR with R (non-ACR-R), 4% had R monotherapy, 3% had non-ACR and 29% had no systemic therapy. Patients not receiving ACR were older and/or had more comorbidities. The unadjusted OS was highest in ACR-R (65%), followed by ACR without R (55%) and non-ACR-R (44%). After adjusting patient covariates, ACR-R showed the best survival (63%). However, OS was comparable between non-ACR-R (52%) and ACR without R (52%). Non-ACR-R could be considered for patients who are poor candidates for ACR.
Details
- Title: Subtitle
- Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile
- Creators
- Yu-Yu Tien - Arnold School of Public Health, University of South CarolinaBrian K Link - Department of Internal Medicine, College of Medicine, University of IowaJohn M Brooks - Arnold School of Public Health, University of South CarolinaKara Wright - Department of Epidemiology, College of Public Health, University of IowaElizabeth Chrischilles - Department of Epidemiology, College of Public Health, University of Iowa
- Resource Type
- Journal article
- Publication Details
- Leukemia & Lymphoma, Vol.56(1), pp.65-71
- DOI
- 10.3109/10428194.2014.903589
- PMID
- 24625326
- PMCID
- PMC4383134
- NLM abbreviation
- Leuk Lymphoma
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Publisher
- Taylor & Francis
- Language
- English
- Date published
- 01/02/2015
- Academic Unit
- Pharmacy; Epidemiology; Internal Medicine
- Record Identifier
- 9983995180602771
Metrics
16 Record Views